Skip to content

INBX · Inhibrx Biosciences, Inc.

Healthcare · −0.7% on Oct 16

☆ Add to watchlist

Updated Oct 17 · 10 feeds behind: FDA drug approvals, 1 day, and 9 more · Every feed →

On this page

The market view

Price chart

The interactive INBX chart (by TradingView) loads here.

Our take

3 rules fired on INBX

In short: none of these rules has solid or some evidence yet, so they show no clear lean on INBX.

How each did in past tests, against similar stocks over 3 months. Past results don't predict future ones.

The 0–100 score for INBX, and which of these rules are open on it right now
Members see one number for how strongly these rules agree on INBX, and the day each rule fired. Better-tested rules count more, and so do different kinds of filings that point the same way.
See pricing →
Already a member? Sign in

Compare with this company’s history

Is disclosure activity unusual?

See how many different insiders or members of Congress reported purchases or sales of INBX. Each bar covers 28 days, by disclosure date. Several trades by one person count once in each group and period.

Latest period: Sep 21, 2026–Oct 18, 2026 · UTC dates · today is excluded

Insider purchases

Short history

Only 0 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual.

Latest 28 days
2
Earlier median
—
Earlier range
—
Distinct filers per 28 daysScale: 0–3
Oct 20, 2025Oct 18, 2026
Earlier periodsLatest 28 daysLimited or missing history

Who appears in the latest period?

Up to three filers; one example disclosure each.

Inspect this period’s filings

The history behind this view

First stored company disclosure: Sep 8, 2026. Newest disclosure across this feed: Oct 16, 2026.

Earlier periods in the comparison: 0. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.

Exact counts, dates and filings for all four categories
Insider purchases · Short history

Only 0 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: —; range: unavailable.

Insider purchases: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 20, 2025–Nov 16, 2025—Unavailable
Nov 17, 2025–Dec 14, 2025—Unavailable
Dec 15, 2025–Jan 11, 2026—Unavailable
Jan 12, 2026–Feb 8, 2026—Unavailable
Feb 9, 2026–Mar 8, 2026—Unavailable
Mar 9, 2026–Apr 5, 2026—Unavailable
Apr 6, 2026–May 3, 2026—Unavailable
May 4, 2026–May 31, 2026—Unavailable
Jun 1, 2026–Jun 28, 2026—Unavailable
Jun 29, 2026–Jul 26, 2026—Unavailable
Jul 27, 2026–Aug 23, 2026—Unavailable
Aug 24, 2026–Sep 20, 20263Partial; excluded
Sep 21, 2026–Oct 18, 2026Latest period2Within stored history
Insider sales · Short history

Only 0 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: —; range: unavailable.

Insider sales: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 20, 2025–Nov 16, 2025—Unavailable
Nov 17, 2025–Dec 14, 2025—Unavailable
Dec 15, 2025–Jan 11, 2026—Unavailable
Jan 12, 2026–Feb 8, 2026—Unavailable
Feb 9, 2026–Mar 8, 2026—Unavailable
Mar 9, 2026–Apr 5, 2026—Unavailable
Apr 6, 2026–May 3, 2026—Unavailable
May 4, 2026–May 31, 2026—Unavailable
Jun 1, 2026–Jun 28, 2026—Unavailable
Jun 29, 2026–Jul 26, 2026—Unavailable
Jul 27, 2026–Aug 23, 2026—Unavailable
Aug 24, 2026–Sep 20, 20261Partial; excluded
Sep 21, 2026–Oct 18, 2026Latest period0Within stored history
Congress purchases · History unavailable

No completed-period disclosures for this company are available in this source. Missing history is not zero activity. Earlier median: —; range: unavailable.

Congress purchases: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 20, 2025–Nov 16, 2025—Unavailable
Nov 17, 2025–Dec 14, 2025—Unavailable
Dec 15, 2025–Jan 11, 2026—Unavailable
Jan 12, 2026–Feb 8, 2026—Unavailable
Feb 9, 2026–Mar 8, 2026—Unavailable
Mar 9, 2026–Apr 5, 2026—Unavailable
Apr 6, 2026–May 3, 2026—Unavailable
May 4, 2026–May 31, 2026—Unavailable
Jun 1, 2026–Jun 28, 2026—Unavailable
Jun 29, 2026–Jul 26, 2026—Unavailable
Jul 27, 2026–Aug 23, 2026—Unavailable
Aug 24, 2026–Sep 20, 2026—Unavailable
Sep 21, 2026–Oct 18, 2026Latest period—Unavailable
Congress sales · History unavailable

No completed-period disclosures for this company are available in this source. Missing history is not zero activity. Earlier median: —; range: unavailable.

Congress sales: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 20, 2025–Nov 16, 2025—Unavailable
Nov 17, 2025–Dec 14, 2025—Unavailable
Dec 15, 2025–Jan 11, 2026—Unavailable
Jan 12, 2026–Feb 8, 2026—Unavailable
Feb 9, 2026–Mar 8, 2026—Unavailable
Mar 9, 2026–Apr 5, 2026—Unavailable
Apr 6, 2026–May 3, 2026—Unavailable
May 4, 2026–May 31, 2026—Unavailable
Jun 1, 2026–Jun 28, 2026—Unavailable
Jun 29, 2026–Jul 26, 2026—Unavailable
Jul 27, 2026–Aug 23, 2026—Unavailable
Aug 24, 2026–Sep 20, 2026—Unavailable
Sep 21, 2026–Oct 18, 2026Latest period—Unavailable
How to read this comparison

The median is the middle count in up to 12 earlier, non-overlapping 28-day periods; the range runs from the smallest to the largest count. The latest period is excluded from both. A comparison needs at least 6 earlier periods, including 3 with activity. The feed’s latest disclosure must be within 7 days of the current period’s end. This freshness check does not verify complete collection.

Insiders include individuals and reporting entities; only purchase and sale codes enter this view. Congress counts reporting members, including their disclosed family transactions. The same filer can appear in purchases and sales, so these categories should not be added into a net count.

These are stored disclosures, not a complete measure of trading. Reporting delays and collection gaps can change the comparison. More activity does not identify a motive or predict a stock’s return.

Company timeline

What has been happening?

May 1, 2026–Oct 16, 2026. Select a month in a category to inspect its records.

Company filings

Insiders

Owners & lobbying

Insiders · Oct 2026

  1. Disclosed
    Mark Lappe · Purchase

    Transaction dated Oct 14, 2026

  2. Disclosed
    Mark Lappe · Purchase

    Transaction dated Oct 14, 2026

  3. Disclosed
    Mark Lappe · Purchase

    Transaction dated Oct 14, 2026

  4. Disclosed
    Mark Lappe · Purchase

    Transaction dated Oct 14, 2026

  5. Disclosed
    Mark Lappe · Purchase

    Transaction dated Oct 14, 2026

All 36 records in this snapshot
  1. Disclosed
    Mark Lappe · Purchase

    Transaction dated Oct 14, 2026

  2. Disclosed
    Mark Lappe · Purchase

    Transaction dated Oct 14, 2026

  3. Disclosed
    Mark Lappe · Purchase

    Transaction dated Oct 14, 2026

  4. Disclosed
    Mark Lappe · Purchase

    Transaction dated Oct 14, 2026

  5. Disclosed
    Mark Lappe · Purchase

    Transaction dated Oct 14, 2026

  6. Filed
  7. Disclosed
    Mark Lappe · Purchase

    Transaction dated Sep 28, 2026

  8. Disclosed
    Mark Lappe · Purchase

    Transaction dated Sep 28, 2026

  9. Disclosed
    Mark Lappe · Purchase

    Transaction dated Sep 25, 2026

  10. Disclosed
    Mark Lappe · Purchase

    Transaction dated Sep 25, 2026

  11. Filed
  12. Disclosed
    Jon Faiz Kayyem · Purchase

    Transaction dated Sep 23, 2026

  13. Disclosed
    Jon Faiz Kayyem · Purchase

    Transaction dated Sep 16, 2026

  14. Disclosed
    Kimberly Manhard · Sale

    Transaction dated Sep 14, 2026

  15. Disclosed
    Kimberly Manhard · Sale

    Transaction dated Sep 15, 2026

  16. Disclosed
    Kimberly Manhard · Sale

    Transaction dated Sep 11, 2026

  17. Filed
  18. Filed
  19. Filed
  20. Disclosed
    Kimberly Manhard · Sale

    Transaction dated Sep 9, 2026

  21. Disclosed
    Kimberly Manhard · Sale

    Transaction dated Sep 8, 2026

  22. Filed
  23. Filed
  24. Disclosed
    Douglas Forsyth · Purchase

    Transaction dated Sep 8, 2026

  25. Disclosed
    Jon Faiz Kayyem · Purchase

    Transaction dated Sep 8, 2026

  26. Disclosed
    Mark Lappe · Purchase

    Transaction dated Sep 8, 2026

  27. Disclosed
    Mark Lappe · Purchase

    Transaction dated Sep 8, 2026

  28. Disclosed
    Mark Lappe · Purchase

    Transaction dated Sep 8, 2026

  29. Disclosed
    Mark Lappe · Purchase

    Transaction dated Sep 8, 2026

  30. Disclosed
    Mark Lappe · Purchase

    Transaction dated Sep 8, 2026

  31. Disclosed
    Mark Lappe · Purchase

    Transaction dated Sep 8, 2026

  32. Filed
  33. Filed
  34. Filed
  35. Filed
  36. Filed

Month counts include every record on file. The lists show the newest records on this page. A dash means none on file that month. Trades use disclosure dates; contract dates follow the source record. Nearby events do not establish the cause of a price move.

Who's buying and selling · last 90 days

Congress

No Congress trades on INBX disclosed in the last 90 days.

See every Congress trade on INBX →

Company insiders

7 buys · 2 sells (24 filed lots) · $279K sold · $6.3M bought

  1. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$208Kdisclosed Oct 14 · filed the same day
  2. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$206Kdisclosed Oct 14 · filed the same day
  3. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$8.6Kdisclosed Oct 14 · filed the same day
  4. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$210Kdisclosed Oct 14 · filed the same day
  5. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$208Kdisclosed Oct 14 · filed the same day
  6. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$148Kdisclosed Sep 28 · filed the same day
  7. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$305Kdisclosed Sep 28 · filed the same day
  8. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$329Kdisclosed Sep 28 · filed 3 days after the trade
  9. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$217Kdisclosed Sep 28 · filed 3 days after the trade
  10. ▲ BUYJon Faiz Kayyem DirectorINBX Inhibrx Biosciences, Inc.$500Kdisclosed Sep 23 · filed the same day
See every insider trade on INBX →

Big holders (Schedule 13D / 13G): 2 filings in the last 90 days · newest: Schonfeld Strategic Advisors LLC (13G), Aug 14, 2026 ↗

Filings & events

Company filings (8-K) 52

Events the company must report to the SEC within days — results, deals, departures, restatements.

What it files 8-Ks about

  • Shared information with investors · item 7.0112
  • Other events · item 8.017
  • Quarterly or yearly results · item 2.026
  • Signed a major agreement · item 1.012
  • Sold shares privately · item 3.022
  • Took on new debt · item 2.031

Filing red flags 5

Warning signs in the company's own SEC filings — going-concern doubts, control weaknesses, staff comment letters, late filings, restatements, Wells notices, clinical holds, dividend cuts.

FDA and clinical trials 1

Drug approvals, recalls, clinical-trial updates and FDA advisory meetings.

Planned insider sales (Form 144) 5

Notices insiders file before they sell certain shares, such as ones they got straight from the company.

5 in the last 90 days · 5 notices on file

The notices on file don't give the sale's size; each sale shows up under company insiders once it is reported.

5% owners (13D / 13G) 7

Investors who reported owning 5% or more — 13D for owners who may push for changes, 13G for owners who just hold.

Push for changes, or just hold?

  • 13D, may push for changes: 2 filings
  • 13G, just holds: 5 filings

Filed most: BlackRock, Inc. (2) · Schonfeld Strategic Advisors LLC (1) · Bank Of America Corp /De/ (1) · Morgan Stanley (1)

Biggest named funds (13F)

The largest INBX holdings among the well-known funds whose quarterly 13F filings we read — opens here.

Every disclosed trade on INBX

  1. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$208Kdisclosed Oct 14 · filed the same day
  2. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$206Kdisclosed Oct 14 · filed the same day
  3. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$8.6Kdisclosed Oct 14 · filed the same day
  4. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$210Kdisclosed Oct 14 · filed the same day
  5. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$208Kdisclosed Oct 14 · filed the same day
  6. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$148Kdisclosed Sep 28 · filed the same day
  7. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$305Kdisclosed Sep 28 · filed the same day
  8. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$329Kdisclosed Sep 28 · filed 3 days after the trade
  9. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$217Kdisclosed Sep 28 · filed 3 days after the trade
  10. ▲ BUYJon Faiz Kayyem DirectorINBX Inhibrx Biosciences, Inc.$500Kdisclosed Sep 23 · filed the same day
  11. ▲ BUYJon Faiz Kayyem DirectorINBX Inhibrx Biosciences, Inc.$500Kdisclosed Sep 17 · filed 1 day after the trade
  12. ▼ SELLKimberly Manhard DirectorINBX Inhibrx Biosciences, Inc.$55.1Kdisclosed Sep 15 · filed 1 day after the trade
  13. ▼ SELLKimberly Manhard DirectorINBX Inhibrx Biosciences, Inc.$52.5Kdisclosed Sep 15 · filed the same day
  14. ▼ SELLKimberly Manhard DirectorINBX Inhibrx Biosciences, Inc.$55.9Kdisclosed Sep 15 · filed 4 days after the trade
  15. ▼ SELLKimberly Manhard DirectorINBX Inhibrx Biosciences, Inc.$57.9Kdisclosed Sep 10 · filed 1 day after the trade
  16. ▼ SELLKimberly Manhard DirectorINBX Inhibrx Biosciences, Inc.$57.6Kdisclosed Sep 10 · filed 2 days after the trade
  17. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$118Kdisclosed Sep 8 · filed the same day
  18. ▲ BUYDouglas Forsyth DirectorINBX Inhibrx Biosciences, Inc.$287Kdisclosed Sep 8 · filed the same day
  19. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$665Kdisclosed Sep 8 · filed the same day
  20. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$136Kdisclosed Sep 8 · filed the same day
  21. ▲ BUYJon Faiz Kayyem DirectorINBX Inhibrx Biosciences, Inc.$568Kdisclosed Sep 8 · filed the same day
  22. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$585Kdisclosed Sep 8 · filed the same day
  23. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$54.1Kdisclosed Sep 8 · filed the same day
  24. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$1.1Mdisclosed Sep 8 · filed the same day
See the trades on INBX in the feed →
People & votes

Which members of Congress traded INBX, sponsored bills that touch it and voted on them — opens here.